Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5444613 | 0.78 | GAA (0.35) | GAAKDM4ERXFP1NPSR1L3MBTL1 | |
| SCHEMBL5444079 | 0.75 | ADORA2A (0.44) | KDM4ERXFP1PIK3CGNPSR1L3MBTL1 | |
| SCHEMBL6312317 | 0.75 | MAPT (0.41) | GAAKDM4ENPSR1NPC1LMNA | |
| SCHEMBL5451528 | 0.74 | KDM1A (0.40) | — | |
| SCHEMBL5451527 | 0.74 | KDM1A (0.33) | — | |
| SCHEMBL6310676 | 0.73 | MAPT (0.59) | GAAKDM4ERXFP1NPSR1NPC1 | |
| SCHEMBL5439279 | 0.68 | RAB9A (0.53) | GAAKDM4EPIK3CGNPSR1L3MBTL1 | |
| SCHEMBL6310683 | 0.67 | KDM4E (0.36) | GAAKDM4ENPSR1L3MBTL1NPC1 | |
| SCHEMBL5439314 | 0.67 | KDM4E (0.39) | GAAKDM4ERXFP1NPC1MAPT | |
| SCHEMBL5449171 | 0.65 | KDM4E (0.42) | GAAKDM4ENPSR1L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1717238-A1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | ERG28, MANBA, MAN2B1 | GAA 23/4885KDM4E 3019/4885RXFP1 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.